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a  b  s  t  r  a  c  t
Aim: To review the clinical feasibility of carbon ion radiotherapy (C-ion RT) for skull base
tumors, especially for chordomas which are often seen in the skull base area.
Background: Skull base tumors treated by C-ion RT consist of primary chordomas and chon-
drosarcomas, and enormously extended head and neck cancer with a histology of adenoid
cystic  carcinomas, adenocarcinomas and malignant melanomas. These tumors are located
on  anatomically complex sites where they are close to important normal tissues and there-
fore  demand better physical dose distribution to avoid unnecessary doses for surrounding
normal tissues. These tumors are also known as radio-resistant tumors for low linear energy
transfer (LET) radiotherapy and show favorable results after treatment by high LET carbon
ion radiotherapy.
Materials and methods: Biological reports of C-ions for the chordoma cell line, clinical results
of  C-ion RT for skull base tumors, dose comparative studies between two  representative
facilities and tumor control probability (TCP) of chordomas by C-ion RT were reviewed.
Results: C-ion RT for skull base tumors, especially for chordomas, shows favorable results
of  tumor control and acceptable complications. The C-ion dose of 57.36 gray equivalent
(GyE)/16 fractions/4 weeks will deliver 90% of local control for chordomas. The limiting doses
for  surrounding normal tissues are clearly revealed. The dose difference between institutes
was  assumed within 10%.Conclusions: C-ion RT is recommended for skull base tumors because of high LET character-
istics and clinical results.
© 2015 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
skull base tumors consist of various histological and clini-1.  BackgroundSkull base tumors are arising in complex anatomical regions
and adjacent to the important normal tissues like the brain,
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cranial nerves, brainstem, eyeball and acoustic system. Alsocal types including chordomas, chondrosarcomas, and other
primary tumors; adenoid cystic carcinomas, adenocarcino-
mas, malignant melanomas and other metastatic and direct
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nvasive tumors from neighboring anatomical sites. Surgical
esection is recommended as the first therapeutic strategy,
cquiring histological details with tumor removal.1 Due to
he proximity of critical normal tissues, complete surgical
esection can result in severe complications of surround-
ng normal tissues. In such a situation, highly conformed
adiotherapy, like intensity modulated radiotherapy (IMRT),
tereotactic radio-surgery (SRS) and charged particles will be
ecommended. Charged particles, like protons and carbon
ons, have a Bragg peak and show better dose distribution than
onventional X-rays, resulting in less doses to the surrounding
ormal tissues.2 For these tumors, high linear energy transfer
LET) radiotherapy is occasionally recommended because the
iological characteristics have a high relative biological effec-
iveness (RBE). Carbon ions (C-ions) are charged particles the
ame as protons, and are characterized as high LET radiothe-
apy, different from low LET protons. The target tumors of high
ET charged particles will be chordomas, chondrosarcomas,
alignant meningiomas and non-squamous cell malignan-
ies of the head and neck.
.  Aim
n this review article, the evidence of the high RBE feature of
-ions for skull base tumors, especially primary chordomas,
hich is the most popular histology in skull base tumors, was
nvestigated in terms of biology, beam delivery, clinical results
nd dose comparative studies.
.  Materials  and  methods
.1.  Biology  of  high  LET  radiation  for  a  chordoma  cell
ine
 chordoma is a rare and slow growing malignancy arising
rom the remnants of the fetal notochord3 and there exist a
ew cell lines of chordomas established for biological study.4,5
lso, the characteristics of the slow growth in chordomas
ake it difficult to investigate the behaviors in radiation expo-
ure. Kato et al. investigated the nature of the U-CH1-N cell
ine which is a subpopulation of U-CH1 chordoma cells with a
hort doubling time.6 They reported the cell doubling time of
-CH1-N as 3 days which was a longer time than other cell
ines, like HeLa (uterine cervix – 18 h) and U87-MG (malig-
ant glioma – 24 h). Using this short-doubling-time cell line,
hey reported the RBE values of U-CH1-N at 10% survival as
.30 in 13 keV/m C-ion, 2.45 in 70 keV/m C-ion and 3.86 in
00 keV/m iron-ion.
Fujisawa et al. followed the comparative study of RBE
etween C-ion and proton therapy for chordomas using the
-CG1-N cell line.7 RBE values were calculated based on the
10 values. The RBE value of 70 MeV  proton was 0.89, of
3–20 keV/m C-ion was 0.85, of 20–30 keV/m C-ion was 1.27,
nd >30 keV/m C-ion was 1.69. C-ion killed cells depending
n both the dose and the LET, while protons depended on the
ose alone. They concluded the carbon ion radiotherapy may
ave an advantage for chordoma radiotherapy because of a
igher cell-killing effect with high LET doses from biological
bservation in their studies.therapy 2 1 ( 2 0 1 6 ) 356–360 357
3.2.  Beam  delivery  and  treatment  planning  system
A present, there are two representative beam delivery systems
for C-ion RT.
One is a passive beam delivery system at the National Insti-
tute of Radiological Sciences (NIRS) in Chiba, Japan, and is
based on the relationships between RBE and LET of human
salivary gland tumor (HSG) cells for flattening the spread out
Bragg peak (SOBP) and on the clinical experience with fast neu-
trons for determining the clinical RBE.8 Accelerated beams are
broadened laterally by wobbler magnets and a scatterer; and
they are longitudinally spread out by a ridge filter. A collimator
and a compensator are used to clip the irradiation fields and
to conform the distal shape of the irradiation field to those
of the planned target volume of a patient, respectively. SOBPs
were designed for the carbon beam to have uniform biological
responses throughout the SOBP. The physical dose distribu-
tions of the beam agreed very well with the predicted depth
dose distributions; also, the biological responses were satis-
factorily flat in the SOBP. RBE values of carbon beams were
determined based on experimental results of cell responses,
on values expected with the linear-quadratic model, and on
experiences with neutron therapy. They use fixed RBE val-
ues independent of dose levels, and the RBE system depends
only on LET of the C-ion radiation fields. The clinical dose is
obtained by multiplying a ratio between the biologic dose at
the neutron-equivalent point and the clinically observed RBE
value, 3.0 to the entire biologic dose distributions.
Another system is a dynamic beam delivery at Gesellschaft
fuer Schwerionenforschung (GSI) in Darmstadt, Germany.9
The RBEs are determined for each single beam through the
local effect model (LEM) which assumes that equal local doses
should lead to equal local effects, independent of the radiation
quality. The first version, LEM I, is based on a radial dose dis-
tribution of each charged particle crossing into a cell nucleus,
as well as on the radiosensitivity and repair capacity of the
tissue. They reported that the original version of the LEM I
underestimated the ratio of RBE in the Bragg peak region as
compared with the RBE in the entrance. The next extension of
the LEM II still showed the same tendency. Implementation of
the modified track structure LEM III almost completely com-
pensates for these systematic deviations, and predictions of
RBE by LEM III for high and low energetic C-ions show good
agreement for a wide panel of different cell lines, as well as
for the tolerance of the rat spinal cord.
3.3.  Clinical  results  of  carbon  ion  radiotherapy
Since December 1997, C-ion radiotherapy (RT) has been per-
formed at the GSI by means of the intensity-controlled raster
scan technique for patients with chordomas and low-grade
chondrosarcomas of the skull base. The median total dose
was 60 gray equivalent (GyE) (57–70 GyE) (weekly fractionation
of 7 fractions with a fraction dose of 3.0 GyE) delivered in 20
fractions within 3 weeks. Schulz-Ertner et al. reported the pre-
liminary results of C-ion RT in 96 patients with chordomas of
the skull base in 2007.10 The actuarial 3- and 5-year local con-
trol rates were 80.6% and 70.0%, respectively, and the overall
3- and 5-year overall survival (OS) rates were 91.8% and 88.5%
with acceptable toxicity. Delivery of target doses exceeding
d rad358  reports of practical oncology an
60 cobalt-gray equivalent (CGE) in 12 patients improved local
control significantly (p = 0.029, log-rank) with a 5-year local
control probability increasing from 63% to 100%. They tried to
demonstrate the dose-tumor control probability (TCP) curves
by means of a logistic model (P(D) = eb0+b1D/(1 + eb0+b1D), where
P is the probability of tumor control, D is the dose (Gy) applied
to the skull base chordoma, and b0 and b1 are constants
requiring estimation for TCP) together with photon and proton
studies. The resulting parameters were b0 = 5.7072, b1 = 0.087
and D50 (dose for 50% tumor control) = 65.6 Gy converting the
carbon dose to the effective dose of 2 Gy per fraction using
˛/ˇ = 2 Gy. Even if there were some uncertainties in the data
used for curve fitting, the reported dose–response relationship
represented that the high dose irradiation would increase the
possibility of chordoma control. Uhl et al. updated long-term
results of C-ion RT for 155 patients with skull base chordomas
treated at the GSI.11 The median follow-up after treatment
was 72 months (range, 12–165 months). The resulting 3-year,
5-year, and 10-year LC rates were 82%, 72%, and 54%, respec-
tively, whereas the 3-year, 5-year, and 10-year OS rates were
95%, 85%, and 75%, respectively. No higher late toxicity could
be detected after carbon ion treatment.
Mizoe et al. reported the results of dose escalation Phase I/II
study of C-ion RT for 33 patients with skull base chordoma at
NIRS in Chiba, Japan.12 All the patients were treated by 16 frac-
tions for 4 weeks with total doses of 48.0, 52.8, 57.6, and 60.8 Gy
equivalents (GyE). The local control rate was 85.1% (standard
error [SE], 8%) at 5 years and 63.8% (SE, 19%) at 10 years. The
OS rate of the 33 patients was 87.7% (SE, 7%) at 5 years and
67% (SE, 14%) at 10 years. With multiportal irradiation and
possibly repeated surgical removals, normal tissues showed
a mild reaction, and no severe morbidity of important organs
occurred. As a result of the dose escalation study of C-ion RT
for skull base tumors, a dose fractionation of 60.8 GyE/16 frac-
tions for 4 weeks was decided as a recommended dose because
of acceptable normal tissue reactions and good local tumor
control.
Schulz-Ertner et al. reported the effectiveness and tox-
icity of carbon ion radiotherapy in chondrosarcomas of the
skull base.13 Between November 1998 and September 2005, 54
patients with low-grade and intermediate-grade chondrosar-
comas of the skull base were treated with C-ion RT using the
raster scan technique at the GSI. All patients had gross resid-
ual tumors after surgery. The median total dose was 60 CGE
(weekly fractionation 7 × 3.0 CGE). The median follow-up was
33 months (range, 3–84 months). Only 2 patients developed
local recurrences. The actuarial local control rates were 96.2%
and 89.8% at 3 and 4 years; OS was 98.2% at 5 years. They con-
cluded that C-ion RT is an effective treatment for low- and
intermediate-grade chondrosarcomas of the skull base offer-
ing high local control rates with low toxicity. Uhl et al. reported
the follow up results of 79 patients with chondrosarcoma
of the skull base added to previous report treated between
1998 and 2008.14 The follow-up period after irradiation was 91
months (range, 3–175 months). The 3-year, 5-year, and 10-year
local control rates were 95.9%, 88%, and 88%, respectively; the
corresponding OS rates were 96.1%, 96.1%, and 78.9%, respec-
tively. They concluded that carbon ion therapy is a safe and
effective treatment in patients with chondrosarcoma of the
skull base.iotherapy 2 1 ( 2 0 1 6 ) 356–360
3.4.  Tolerance  doses  of  surrounding  normal  tissues
Hasegawa et al. reported the tolerance dose for retention of
visual acuity in C-ion RT.15 Of 163 patients with H&N and skull
base tumor treated between 1994 and 2000, 54 optic nerves
of 30 patients were included in the irradiation volume. All
patients had a follow-up period of more  than 4 years. The
median prescribed total dose was 56.0 gray equivalents (GyE)
at 3.0–4.0 GyE per fraction per day (range, 48–64 GyE; 16–18 frac-
tions; 4–6 weeks). Of 54 optic nerves (ONs), 35 ONs had been
irradiated under 57 GyE (maximum dose [Dmax]) resulting in no
visual loss. Conversely, 11 of the 19 ONs (58%) irradiated with
more  than 57 GyE (Dmax) suffered a decrease of visual acuity. In
all of these 19 cases, the ONs had been involved in the tumor
before carbon ion radiotherapy. In the multivariate analysis,
a dose of 20% of the volume of the ON (D20) was  significantly
associated with visual loss. They concluded that the occur-
rence of visual loss seemed to be correlated with a delivery of
more than 60 GyE to the 20% of the ON volume.
Koto et al. reported the risk factors of radiation induced
brain injury, which consisted of damage to the temporal lobes,
frontal lobes, and cerebellum, after C-ion radiotherapy for
skull base tumors.16 Between April 1997 and January 2009,
47 patients with skull base tumors were irradiated by C-ion
RT with a total dose of 48.0–60.8 GyE/16 fractions/4 weeks. Of
these patients, 39 who were followed up with magnetic reso-
nance imaging (MRI) for more  than 24 months were analyzed.
The median follow-up period was 67 months. They reported
the occurrence rate of grade 2 or higher brain injury at 5 years
was  34.3% for the patients with V50 larger than 4.6 ml,  and
15.6% for the patients with V50 smaller than 4.6 ml  (p = 0.0192).
They concluded that the occurrence of grade 2 or higher brain
injury correlated with the irradiated volume (4.6 ml)  of V50
(p = 0.004, hazard ratio = 1.229, 95% CI = 1.069–1.412).
3.5.  Dose  comparative  study  between  two
representative  facilities
Uzawa et al. reported the comparative study of the biologi-
cal effectiveness of 290 MeV/amu carbon-ion beams in Chiba,
Japan, and in Darmstadt, Germany. The overall difference of
RBE between the two facilities was 0–5% for gut crypt survival
and 3–7% for HSG cell killing.17 They concluded the carbon-ion
beams at the NIRS, Japan, and the GSI, Germany, are biologi-
cally identical after single and daily fractionated irradiation.
Fossati et al. reported the comparison results of C-ion treat-
ment planning systems (TPSs) between NIRS and GSI.18 In this
study, carbon ion plans were optimized on target volumes of
cubic and spherical shapes, for RBE weighted dose prescrip-
tion levels ranging from 3.6 to 4.4 GyE by 0.2 GyE steps. Plans
were calculated for target sizes from 4 to 12 cm in steps of
2 cm defining three beam geometries which were single beam,
opposed beam and orthogonal beam configurations. Physical
dose distributions of NIRS-based and LEM-based treatment
plans were compared. LEM-based prescription doses that min-
imize differences in physical dose distributions between the
two systems were found. These doses were compared with
the mean RBE-weighted dose obtained with a Monte Carlo
code (FLUKA) interfaced with LEM I. In the investigated dose
range, LEM-based RBE weighted prescription doses should be
reports of practical oncology and radio
Fig. 1 – Dose and tumor control probability (TCP) curve


































as 52.48 GyE and the 90% dose was 57.36 GyE.
igher than NIRS reported prescription doses. The optimal
ose depends on a target size, shape and position, number
f beams and dose level. The opposed beam configuration
esulted in the smallest average prescription dose difference
0.45 ± 0.09 GyE). The second approach of recalculating the
BE-weighted dose of NIRS with a Monte Carlo code interfaced
ith LEM resulted in no significant difference with the results
btained from the planning study.
.  Results
CP  of  carbon  ion  radiotherapy  for  skull  base  chordomas
rom the clinical data of Mizoe et al.,12 tumor control probabil-
ty (TCP) of chordomas treated by carbon ions was estimated.
his curve was calculated from the results of a single insti-
utional and prospective dose escalation study. The objective
atients were 16 cases treated by a phase I/II dose escalation
tudy and 14 cases treated by a phase II study. One case treated
y 48.0 GyE/16 fractions/4 weeks in the phase I/II study was
xcluded from analysis because it was the only one treated
y 48.0 GyE. The local control rate on each dose points were
7% (2/3) at 52.8 GyE, 71% (5/7) at 57.6 GyE and 100% (19/19) at
0.8 GyE. The formula used was the following integral logistic
odel:
 = 1 − 1
(1 + exp(a + b × D))
here P is the probability of local control, D is the dose
GyE) applied to the skull base chordoma, and a and b are
onstants requiring estimation for TCP. For the calculation
f the constants, the least squares method was applied.
onstant a and constant b were estimated at −23.6473 and
.4506, respectively (Fig. 1). From the calculated equation, the
0% local control dose was 52.48 GyE and the 90% dose was
7.36 GyE.therapy 2 1 ( 2 0 1 6 ) 356–360 359
5.  Discussion
The chordoma cell line showed a high RBE nature for C-ion
RT. The RBE was 1.69 in more  than 30 keV/m C-ion7 and 2.45
in 70 keV/m of C-ion.6 The RBE of chordoma cells showed
dose dependency for C-ion irradiation.8 Clinical reports also
showed high RBE results for chordoma,12,14 chondrosarcoma14
and other skull base tumors. These results should confirm the
clinical position of C-ion RT in the management of skull base
tumors.
The high RBE nature of C-ions is not only seen in tumor con-
trol but also in normal tissue reactions. Many  clinical results
showed acceptable morbidity of C-ion RT, and some litera-
ture reported the dose-complication relationships of the optic
nerves15 and the brain.16 These data and other reports19,20 of
C-ion RT showed the clinical feasibility of C-ion RT for skull
base tumors because of the acceptable morbidity of surround-
ing normal tissues.
Ares et al. reported the 5-year local control rates as 81%
for chordomas and 94% for chondrosarcomas in their spot-
scanning proton RT.21 They observed 4 patients (6%) with a
high grade late toxicity. Deraniyagala et al. reported the 2-year
local control rates of proton therapy as 86% for chordomas.22
They observed Grade 2 toxicity in 18% of the patients in
the form of unilateral hearing loss. No grade 2 or higher
optic or brainstem toxicities were observed. These results of
proton RT for chordomas and chondrosarcomas showed clini-
cally acceptable results. Future results of proton RT with dose
escalation and for different histology tumors other than chor-
domas and chondrosarcomas will be needed.
6.  Conclusions
It is clear that the C-ion RT should be favorable in radiothe-
rapy for skull base tumors because of high LET effects for the
tumors and conformed dose distribution for the normal tis-
sues resulting in a high tumor control rate and acceptable
normal tissue morbidity.
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